Evidence map›Paper›PMID 35458618›Full record

ArticleMolecules (Basel, Switzerland)2022

Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-

Mohamed Nabil Abd Al Moaty, El Sayed Helmy El Ashry, Laila Fathy Awad, Nihal Ahmed Ibrahim, Marwa Muhammad Abu-Serie, Assem Barakat, Mezna Saleh Altowyan, Mohamed Teleb

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Mohamed Nabil Abd Al MoatyChemistry Department, Faculty of Science, Alexandria University, Alexandria 21321, Egypt.ORCID 0000-0003-2843-9704
El Sayed Helmy El AshryChemistry Department, Faculty of Science, Alexandria University, Alexandria 21321, Egypt.
Laila Fathy AwadChemistry Department, Faculty of Science, Alexandria University, Alexandria 21321, Egypt.
Nihal Ahmed IbrahimChemistry Department, Faculty of Science, Alexandria University, Alexandria 21321, Egypt.
Marwa Muhammad Abu-SerieMedical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt.
Assem BarakatDepartment of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-7885-3201
Mezna Saleh AltowyanDepartment of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.ORCID 0000-0002-7038-8018
Mohamed TelebDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Alexandria University · EGCity of Scientific Research and Technological Applications · EGKing Saud University · SAPrincess Nourah bint Abdulrahman University · SA

Funding

Princess Nourah bint Abdulrahman University PNURSP2022R86
6 · The paper itself

Abstract

The role of metalloenzymes in tumor progression had broadened their application in cancer therapy. Of these, MMPs and CAs are validated druggable targets that share some pivotal signaling pathways. The majority of MMPs or CAs inhibitors are designed as single-target agents. Despite their transient efficacy, these agents are often susceptible to resistance. This set the stage to introduce dual inhibitors of correlated MMPs and CAs. The next step is expected to target the common vital signaling nodes as well. In this regard, VEGFR-2 is central to various tumorigenesis events involving both families, especially MMP-2 and CA II. Herein, we report simultaneous inhibition of MMP-2, CA II, and VEGFR-2 via rationally designed hybrid 1,2,4-triazolo[4,3-

Indexed as

Antineoplastic AgentsMetalloproteinsNucleosidesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMatrix Metalloproteinase 2Molecular Docking SimulationMolecular StructureProtein Kinase InhibitorsPyrimidinonesStructure-Activity RelationshipTriazolesVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsMatrix Metalloproteinase 2MetalloproteinsNucleosidesProtein Kinase InhibitorsPyrimidinonesTriazolesVascular Endothelial Growth Factor Receptor-21,2,4-triazolo[4,3-a]pyrimidinone acyclo C-nucleosidesCAIIMMP-2multitarget anticancer agentsVEGFR-2

Identifiers

PMID35458618
PMCPMC9026109
OpenAlexW4224248887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.